Search Results - shilpa+kadam

2 Results

Sort By:

Repurposing Perampanel to treat SYNGAP1-related disorders

Value Proposition:· First Targeted Pharmacologic Therapy for SYNGAP1 (MRD5): Introduces the first mechanism-driven treatment strategy for SYNGAP1-related neurodevelopmental disorders, addressing sleep and behavioral dysfunction at the synaptic circuitry level.· Repurposing of an FDA Approved Drug: Utilizes Perampanel (PMP), an already FDA-approved...

Published: 1/22/2026 | Inventor(s): Shilpa Kadam

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies, Technology Classifications > Therapeutic Modalities

Method for Treating Refractory Seizures Using a Novel Therapeutic Approach

Technology OverviewThe invention provides novel pharmaceutical interventions that convert phenobarbital (PB)-resistant seizures into phenobarbital responsive seizures in neonates. We have shown that unlike in adult brains, expression of a transport protein in the neonatal brain is much lower and undergoes further down-regulation following an ischemic...

Published: 1/22/2026 | Inventor(s): Shilpa Kadam

Keywords(s): Agonists/Promoters, CNS and Neurological Disorders, Disease Indication, Epilepsy, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology > Epilepsy, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities